ADARx Pharmaceuticals, Inc. (ADRX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ADRX"
      ],
      "issuer_cik": "0001802369",
      "owner_cik": "0001808744",
      "accession_number": "0000947871-26-000910",
      "form_type": "4",
      "filing_date": "2026-09-30",
      "period_of_report": "2026-09-28",
      "issuer_name": "ADARx Pharmaceuticals, Inc.",
      "issuer_trading_symbol": "ADRX",
      "owner_name": "OrbiMed Genesis GP LLC",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": true,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-09-28",
      "transaction_code": "P",
      "equity_swap_involved": false,
      "transaction_shares": 588235,
      "transaction_price_per_share": 17,
      "transaction_acquired_disposed": "A",
      "shares_owned_following_transaction": 588235,
      "transaction_value": 9999995,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See footnotes",
      "footnotes": [
        {
          "id": "F2",
          "description": "Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."
        },
        {
          "id": "F5",
          "description": "These securities are held directly by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis."
        },
        {
          "id": "F6",
          "description": "This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."
        }
      ]
    },
    {
      "tickers": [
        "ADRX"
      ],
      "issuer_cik": "0001802369",
      "owner_cik": "0001760648",
      "accession_number": "0000947871-26-000910",
      "form_type": "4",
      "filing_date": "2026-09-30",
      "period_of_report": "2026-09-28",
      "issuer_name": "ADARx Pharmaceuticals, Inc.",
      "issuer_trading_symbol": "ADRX",
      "owner_name": "OrbiMed Capital GP VII LLC",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": true,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-09-28",
      "transaction_code": "P",
      "equity_swap_involved": false,
      "transaction_shares": 61516,
      "transaction_price_per_share": 17,
      "transaction_acquired_disposed": "A",
      "shares_owned_following_transaction": 9292025,
      "transaction_value": 1045772,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See footnotes",
      "footnotes": [
        {
          "id": "F2",
          "description": "Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."
        },
        {
          "id": "F4",
          "description": "These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."
        },
        {
          "id": "F6",
          "description": "This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, and Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.